KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Neogenomics (NEO) Research & Development (2016 - 2026)

Neogenomics filings provide 16 years of Research & Development readings, the most recent being $9.5 million for Q1 2026.

  • On a quarterly basis, Research & Development fell 6.35% to $9.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was $36.4 million, a 8.04% increase, with the full-year FY2025 number at $37.1 million, up 18.99% from a year prior.
  • Research & Development hit $9.5 million in Q1 2026 for Neogenomics, up from $9.2 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $10.2 million in Q1 2025 to a low of $5.3 million in Q3 2023.
  • Median Research & Development over the past 5 years was $7.7 million (2022), compared with a mean of $8.0 million.
  • Biggest five-year swings in Research & Development: soared 214.05% in 2022 and later decreased 27.72% in 2023.
  • Neogenomics' Research & Development stood at $6.7 million in 2022, then grew by 6.77% to $7.1 million in 2023, then rose by 11.81% to $8.0 million in 2024, then rose by 15.18% to $9.2 million in 2025, then rose by 3.87% to $9.5 million in 2026.
  • The last three reported values for Research & Development were $9.5 million (Q1 2026), $9.2 million (Q4 2025), and $8.7 million (Q3 2025) per Business Quant data.